See more : Netcapital Inc. (NCPL) Income Statement Analysis – Financial Results
Complete financial analysis of Ensysce Biosciences, Inc. (ENSC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ensysce Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Shine Justice Ltd (SHJ.AX) Income Statement Analysis – Financial Results
- SHRYDUS INDUSTRIES LIMITED (SHRYDUS.BO) Income Statement Analysis – Financial Results
- iBio, Inc. (IBIO) Income Statement Analysis – Financial Results
- Muller & Phipps (India) Limited (MULLER.BO) Income Statement Analysis – Financial Results
- Gujarat Investa Limited (GUJINV.BO) Income Statement Analysis – Financial Results
Ensysce Biosciences, Inc. (ENSC)
About Ensysce Biosciences, Inc.
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.23M | 2.52M | 3.53M | 3.93M | 1.76M | 0.00 | 0.00 |
| Cost of Revenue | 7.59M | 19.84M | 151.00 | 1.37M | 3.33M | 1.56M | 0.00 |
| Gross Profit | -5.36M | -17.31M | 3.53M | 2.56M | -1.56M | -1.56M | 0.00 |
| Gross Profit Ratio | -240.17% | -686.08% | 100.00% | 65.18% | -88.70% | 0.00% | 0.00% |
| Research & Development | 7.59M | 19.84M | 4.69M | 4.39M | 3.40M | 0.00 | 0.00 |
| General & Administrative | 5.36M | 6.91M | 18.71M | 1.15M | 6.93M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | -3.60M | 0.00 | 0.00 |
| SG&A | 5.36M | 6.91M | 18.71M | 1.15M | 3.33M | 1.56M | 146.70K |
| Other Expenses | -7.59M | -2.52M | -3.53M | -3.93M | 0.00 | 600.00K | 0.00 |
| Operating Expenses | 5.36M | 24.22M | 19.87M | 1.61M | 3.33M | 959.25K | 146.70K |
| Cost & Expenses | 12.95M | 24.22M | 19.87M | 1.61M | 3.33M | 959.24K | 146.70K |
| Interest Income | 0.00 | 1.25M | 3.22M | 719.65K | 4.25M | 3.63M | 0.00 |
| Interest Expense | 353.95K | 109.53K | 1.30M | 995.50K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 0.00 | 151.00 | 151.00 | 201.00 | 201.00 | 161.14K | 0.00 |
| EBITDA | -10.72M | -24.22M | -19.87M | -1.61M | 921.15K | 2.68M | -27.56K |
| EBITDA Ratio | -480.52% | -959.91% | -562.71% | -41.03% | -188.70% | 0.00% | 0.00% |
| Operating Income | -10.72M | -24.22M | -19.87M | -1.61M | -3.33M | -959.24K | -146.70K |
| Operating Income Ratio | -480.52% | -959.91% | -562.71% | -41.04% | -188.70% | 0.00% | 0.00% |
| Total Other Income/Expenses | 91.91K | 14.41K | -9.28M | 1.45M | 4.25M | 3.64M | 119.14K |
| Income Before Tax | -10.63M | -24.21M | -29.15M | -160.88K | 921.15K | 2.68M | -27.56K |
| Income Before Tax Ratio | -476.40% | -959.33% | -825.38% | -4.09% | 52.22% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 753.88K | -151.00 | 777.85K | -555.20K | 553.92K | 3.64K |
| Net Income | -10.61M | -24.96M | -29.15M | -938.73K | 1.48M | -1.34M | -31.19K |
| Net Income Ratio | -475.81% | -989.21% | -825.38% | -23.88% | 83.70% | 0.00% | 0.00% |
| EPS | -4.69 | -138.73 | -346.90 | -14.29 | 15.02 | -12.91 | -0.30 |
| EPS Diluted | -4.69 | -138.73 | -346.90 | -13.65 | 15.02 | -12.91 | -0.30 |
| Weighted Avg Shares Out | 2.26M | 179.93K | 84.02K | 65.70K | 98.26K | 104.02K | 105.00K |
| Weighted Avg Shares Out (Dil) | 2.26M | 179.93K | 84.02K | 68.78K | 98.26K | 104.02K | 105.00K |
Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024
Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants
Ensysce Biosciences Announces IRB Approval for Key MPAR Study
Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection
Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)
Ensysce Biosciences Reports Second Quarter 2024 Financial Results
Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium
Ensysce Biosciences Provides Mid-Year 2024 Update
Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset
Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting
Source: https://incomestatements.info
Category: Stock Reports